Insider Transactions in Q3 2024 at Agios Pharmaceuticals, Inc. (AGIO)
Insider Transaction List (Q3 2024)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Sep 26
2024
|
Cecilia Jones Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
2,542
-11.2%
|
$124,558
$49.03 P/Share
|
|
Sep 26
2024
|
Cecilia Jones Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
7,473
+24.77%
|
-
|
|
Aug 11
2024
|
Rahul D. Ballal Director |
BUY
Exercise of conversion of derivative security
|
Direct |
2,302
+22.36%
|
-
|
|
Aug 11
2024
|
Cynthia Smith Director |
BUY
Exercise of conversion of derivative security
|
Direct |
2,302
+22.36%
|
-
|
|
Aug 08
2024
|
Brian Goff Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
11,091
-12.34%
|
$465,822
$42.75 P/Share
|
|
Aug 08
2024
|
Brian Goff Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
22,691
+20.16%
|
-
|
|
Jul 01
2024
|
Sarah Gheuens Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
3,705
-7.81%
|
$159,315
$43.85 P/Share
|
|
Jul 01
2024
|
Sarah Gheuens Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
8,375
+15.0%
|
-
|